期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 157, 期 -, 页码 37-49出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2018.07.061
关键词
Proliferation; Anticancer drug; Phosphatidylinositol 3-kinase inhibitor; Apoptosis; Structure-activity relationship
资金
- National Natural Science Foundation of China [21572027]
- Ministry of Science and Technology of China [2014DFG32200]
- Shanghai Science and Technology Development Fund [15DZ2291600]
- Thousand Talents Program in China
Phosphatidylinositol 3-kinase alpha (PI3K alpha) is the most frequently mutated kinase in human cancers, making it an attractive therapeutic target for cancer treatment. We identified a structurally novel PI3K alpha H1047R mutant inhibitor Hit-01 (EC50 = 76.0 mu M) through a high-throughput screening campaign. Chemical optimizations enabled us to discover compound 7b, which strongly inhibited PI3K alpha H1047R mutant with an EC50 value of 0.137 mu M, over 500-fold more potent than Hit-01. Western blotting analysis suggested that 7b could decrease the phosphorylation level of p-AKT, another proof that 7b inhibited PI3K alpha H1047R function. Cell viability assay revealed that 7b inhibited HCT116 cancer cell growth with an IC50 value of 11.23 mu M. In addition, 7b was found to arrest cell cycle at G1 phase and induce cell apoptosis via up regulation of caspase-3, caspase-8 and caspase-9 protein expressions. Collectively, all these data demonstrated that 7b could be a promising lead for the development of structurally novel PI3K alpha inhibitors. (C) 2018 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据